Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo

Jai Jen Tsai, Fei Ting Hsu, Po Jung Pan, Chia Wen Chen, Yu Cheng Kuo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.

Original languageEnglish
Pages (from-to)2119-2125
Number of pages7
JournalAnticancer Research
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Hepatocellular Carcinoma
Apoptosis
Therapeutics
Neoplasms
Apoptosis Regulatory Proteins
sorafenib
amentoflavone
Growth
Immunohistochemistry
Body Weight
Phosphorylation
Staining and Labeling

Keywords

  • AKT
  • Amentoflavone
  • Apoptosis.
  • ERK
  • Hepatocellular carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo. / Tsai, Jai Jen; Hsu, Fei Ting; Pan, Po Jung; Chen, Chia Wen; Kuo, Yu Cheng.

In: Anticancer Research, Vol. 38, No. 4, 01.04.2018, p. 2119-2125.

Research output: Contribution to journalArticle

Tsai, Jai Jen ; Hsu, Fei Ting ; Pan, Po Jung ; Chen, Chia Wen ; Kuo, Yu Cheng. / Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo. In: Anticancer Research. 2018 ; Vol. 38, No. 4. pp. 2119-2125.
@article{7e1e1fa2aac74c6388ca5b16cc94e591,
title = "Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo",
abstract = "Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.",
keywords = "AKT, Amentoflavone, Apoptosis., ERK, Hepatocellular carcinoma, Sorafenib",
author = "Tsai, {Jai Jen} and Hsu, {Fei Ting} and Pan, {Po Jung} and Chen, {Chia Wen} and Kuo, {Yu Cheng}",
year = "2018",
month = "4",
day = "1",
doi = "10.21873/anticanres.12452",
language = "English",
volume = "38",
pages = "2119--2125",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo

AU - Tsai, Jai Jen

AU - Hsu, Fei Ting

AU - Pan, Po Jung

AU - Chen, Chia Wen

AU - Kuo, Yu Cheng

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.

AB - Background/Aim: In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro. However, whether amentoflavone augments anticancer efficacy of sorafenib in HCC in vivo is unknown. The aim of the present study was to verify the anticancer effect of amentoflavone combined with sorafenib in HCC in vivo. Materials and Methods: HCC SK-Hep1 tumor-bearing mice were treated with vehicle, sorafenib, amentoflavone, or combination for 14 days, respectively. Effect of sorafenib, amentoflavone, or their combination on tumor growth, anti-apoptotic potential, apoptotic signaling and general toxicity were evaluated with digital caliper, immunohistochemistry staining and body weight. Results: Our results demonstrated that amentoflavone significantly enhanced sorafenib-inhibited tumor growth and expression of ERK/AKT phosphorylation and anti-apoptotic proteins compared to single-agent treatment. Additionally, amentoflavone also triggered sorafenib-induced apoptosis through extrinsic and intrinsic apoptotic pathways. Conclusion: Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.

KW - AKT

KW - Amentoflavone

KW - Apoptosis.

KW - ERK

KW - Hepatocellular carcinoma

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85045207671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045207671&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12452

DO - 10.21873/anticanres.12452

M3 - Article

AN - SCOPUS:85045207671

VL - 38

SP - 2119

EP - 2125

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -